Search results
Showing 16 to 30 of 91 results for cholesterol
Improved identification of familial hypercholesterolaemia (FH) in primary care
decision-making in considering a diagnosis of FH in adults and children with raised cholesterol. After initial positive results showed...
Sotagliflozin with insulin for treating type 1 diabetes (TA622)
Evidence-based recommendations on sotagliflozin with insulin for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m2 , when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.
This quality standard covers prevention of type 2 diabetes in adults (aged 18 and over) and care and treatment for adults with type 2 diabetes. It describes high-quality care in priority areas for improvement.
View quality statements for QS209Show all sections
Sections for QS209
- Quality statements
- Quality statement 1: Preventing type 2 diabetes
- Quality statement 2: Structured education programme
- Quality statement 3: Continuous glucose monitoring for adults on multiple daily insulin injections who cannot self-monitor using capillary blood glucose monitoring
- Quality statement 4: Continuous glucose monitoring for adults who use insulin and need help monitoring their blood glucose
- Quality statement 5: Treatment with an SGLT2 inhibitor
- Quality statement 6: 9 key care processes
- Quality statement 7: Assessing the risk of diabetic foot problems on admission to hospital
This indicator covers the proportion of adults with diabetes who have received all 9 basic care processes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG13
Evidence-based recommendations on bempedoic acid with ezetimibe (Nilemdo and Nustendi) for treating primary hypercholesterolaemia or mixed dyslipidaemia as an adjunct to diet in adults.
Summary of the evidence on colesevelam for treating bile acid malabsorption (BAM) to inform local NHS planning and decision-making
This quality standard covers diagnosing and managing lower limb peripheral arterial disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS52Show all sections
Sections for QS52
- Quality statements
- Quality statement 1: Identification and assessment of peripheral arterial disease
- Quality statement 2: Comorbidity assessment
- Quality statement 3: Supervised exercise programmes
- Quality statement 4: Imaging
- Quality statement 5: Angioplasty for intermittent claudication
- About this quality standard
Find out more about the progress made in implementing NICE guidance on cardiovascular disease prevention
Question What is the effectiveness of statins and/or other LDL-cholesterol-lowering treatment in people with type 1 diabetes? Any...
This quality standard covers managing hypertension in adults. It includes diagnosis and investigations, treatment and specialist referral. It describes high-quality care in priority areas for improvement.
View quality statements for QS28Show all sections
Sections for QS28
- Quality statements
- Quality statement 1: Diagnosis – ambulatory blood pressure monitoring
- Quality statement 2: Investigations for target organ damage
- Quality statement 3: Statin therapy
- Quality statement 4: Blood pressure targets
- Quality statement 5: Review of cardiovascular disease risk factors
- Quality statement 6: Referral to a specialist for adults with resistant hypertension
- Update information
Cardiovascular disease. Patient decision aid on should I take a statin?
These blockages or reduced blood flow are often caused by a build-up of cholesterol in blood vessel walls. Angina can make it difficult...
targets for glycated haemoglobin (HbA1c), blood pressure (BP) or total cholesterol (TC) readings were not being achieved. The proportion...
This indicator covers the percentage of patients with type 1 diabetes who are aged over 40 years currently treated with a statin. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM142
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)
Evidence-based recommendations on inclisiran (Leqvio) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
Kidney conditions: CKD and lipid lowering therapies (IND231)
This indicator covers the percentage of patients with CKD, on the register, who are currently treated with a lipid-lowering therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM213